Harrow Health, Inc.

NASDAQ:HROW

Drug Manufacturers - Specialty & Generic

Healthcare
$32.16 +0.29%

+$0.12 today

Market cap
$1.21B
Beta
0.28
P/E (TTM)
-104.7
EPS (TTM)
-$0.40
52W Low $28.54High $54.85

Volume 0.87M

Average 0.75M

HROW Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Harrow Health, Inc.NASDAQ: HROW

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 37.23M shares rose 3.9% year over year, behind the +6.1% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 1.3% from the prior quarter. Over 3 fiscal years it compounded at +10.2% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +3.9% toward the trailing-twelve-month pace of +6.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
37.23M+1.3% QoQ
Last fiscal yearDec 2025
36.76M+3.1% YoY
LTMMar 2026
37.93M+6.1% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.9%——
1 year+3.1%——
3-year CAGR+10.2%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
36.76M USD
Year-over-year change
+3.1%
4-year CAGR
+8.3%

Weighted Avg Shares (Diluted) vs competitors

How HROW compares with its peers on the latest reported figures

  • HROW's LTM Mar 2026 weighted avg shares (diluted) of 37.93M shares is the 7th highest of the 9 companies compared; the peer median is 57.56M shares.
  • Its year-over-year change of +6.1% is the 7th highest of 8, against a peer median of +14.4%.
  • Over three fiscal years its annual growth of +10.2% compares with a peer median of +19.3%.
HROW Competitors Peer median
Weighted Avg Shares (Diluted) for HROW and competitors
Company Period LTM YoY 3-year CAGR
BLCOBausch + Lomb CorporationLTM Jun 2026355.23M +0.6%+0.4%
OCULOcular Therapeutix, Inc.LTM Mar 2026200.88M +19.9%+31.3%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 202677.28M +27.7%+25.2%
KODKodiak Sciences Inc.LTM Sep 202660.16M +14.0%+0.6%
OCSOculis Holding AGLTM Mar 202654.96M +27.5%+16.9%
TARSTarsus Pharmaceuticals, Inc.LTM Sep 202643.89M +7.8%+19.3%
HROWHarrow Health, Inc.LTM Mar 202637.93M +6.1%+10.2%
OTLKOutlook Therapeutics, Inc.LTM Mar 202628.35M +14.4%+33.9%
TTRXTurn Therapeutics Inc.LTM Mar 202625.17M ——
Peer median (excluding HROW) 57.56M+14.4%+19.3%

Competitors are the stored peer set for HROW. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue72.48M88.6M130.19M199.61M272.3M
Cost of Revenue18.21M25.38M39.64M49.25M67.93M
Gross Profit54.26M63.21M90.55M150.37M204.37M
Gross Margin74.9%71.3%69.6%75.3%75.1%
Research & Development11.08M3.05M6.65M12.23M12.85M
Selling, General & Admin39.82M000152.91M
Operating Expenses52.65M61.29M90.12M141.55M165.76M
Depreciation & Amortization1.74M2.83M11.14M13.05M18.91M
EBITDA5.1M(3.94M)11.95M22.13M41.36M
EBITDA Margin7.0%-4.4%9.2%11.1%15.2%
Operating Income1.61M1.92M431K8.82M38.61M
Operating Margin2.2%2.2%0.3%4.4%14.2%
Interest Income00000
Interest Expense5.44M7.24M21.32M22.79M24.18M
Other Income / Expenses(19.49M)(15.93M)(24.14M)(26.14M)(40.33M)
Income Before Tax(17.87M)(14.01M)(23.71M)(17.32M)(1.72M)
Pre-Tax Margin-24.7%-15.8%-18.2%-8.7%-0.6%
Income Tax Expense133K75K701K161K3.42M
Net Income(18.01M)(14.09M)(24.41M)(17.48M)(5.14M)
Net Margin-24.8%-15.9%-18.7%-8.8%-1.9%
EPS (Basic)(0.69)(0.51)(0.75)(0.49)(0.14)
EPS (Diluted)(0.69)(0.51)(0.75)(0.49)(0.14)
Weighted Avg Shares26.76M27.46M32.62M35.65M36.76M
Weighted Avg Shares (Diluted)26.76M27.46M32.62M35.65M36.76M

Harrow Health, Inc.

NASDAQ:HROW

Intrinsic Alpha fair value

Locked

Current Price

$32.16

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.